Articles from Antidepressants

Primary tabs

Janssen gets another NICE rejection for its Spravato - The Pharma Letter

Submitted by Anonymous (not verified) on Thu, 09/03/2020 - 13:56

Janssen gets another NICE rejection for its Spravato The Pharma Letter

Read more about Janssen gets another NICE rejection for its Spravato - The Pharma Letter
Log in to post comments

Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants - BioSpace

Submitted by Anonymous (not verified) on Thu, 09/03/2020 - 12:52

Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants BioSpace

Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants - StreetInsider.com

Submitted by Anonymous (not verified) on Thu, 09/03/2020 - 12:37

Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants StreetInsider.com

Antidepressant Drugs Industry 2020 – Market Size, Share, Price, Trend And Forecast To 2026- DataIntelo - Scientect

Submitted by Anonymous (not verified) on Thu, 09/03/2020 - 10:45

Antidepressant Drugs Industry 2020 – Market Size, Share, Price, Trend And Forecast To 2026- DataIntelo Scientect

Tricyclic Antidepressant Market – Qualitative Analysis on Demand 2025 - Scientect

Submitted by Anonymous (not verified) on Thu, 09/03/2020 - 10:00

Tricyclic Antidepressant Market – Qualitative Analysis on Demand 2025 Scientect

Read more about Tricyclic Antidepressant Market – Qualitative Analysis on Demand 2025 - Scientect
Log in to post comments

The trouble with antidepressants: why the evidence overplays benefits and underplays risks—an essay by John B Warren - The BMJ

Submitted by Anonymous (not verified) on Thu, 09/03/2020 - 09:58

The trouble with antidepressants: why the evidence overplays benefits and underplays risks—an essay by John B Warren The BMJ

Depression Drugs Market Size, share | Growth Forecast till 2020-2025 – The Daily Chronicle - The Daily Chronicle

Submitted by Anonymous (not verified) on Thu, 09/03/2020 - 09:20

Depression Drugs Market Size, share | Growth Forecast till 2020-2025 – The Daily Chronicle The Daily Chronicle

Janssen disappointed with second NICE no for Spravato - PharmaTimes

Submitted by Anonymous (not verified) on Thu, 09/03/2020 - 07:13

Janssen disappointed with second NICE no for Spravato PharmaTimes

Read more about Janssen disappointed with second NICE no for Spravato - PharmaTimes
Log in to post comments

Combination Therapy for Treatment-Resistant Schizophrenia? - Psychiatric Times

Submitted by Anonymous (not verified) on Thu, 09/03/2020 - 07:00

Combination Therapy for Treatment-Resistant Schizophrenia? Psychiatric Times

Read more about Combination Therapy for Treatment-Resistant Schizophrenia? - Psychiatric Times
Log in to post comments

Re: The trouble with antidepressants: why the evidence overplays benefits and underplays risks—an essay by John B Warren - The BMJ

Submitted by Anonymous (not verified) on Thu, 09/03/2020 - 07:00

Re: The trouble with antidepressants: why the evidence overplays benefits and underplays risks—an essay by John B Warren The BMJ

Main menu

Articles from Antidepressants

Primary tabs

Janssen gets another NICE rejection for its Spravato - The Pharma Letter

Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants - BioSpace

Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants - StreetInsider.com

Antidepressant Drugs Industry 2020 – Market Size, Share, Price, Trend And Forecast To 2026- DataIntelo - Scientect

Tricyclic Antidepressant Market – Qualitative Analysis on Demand 2025 - Scientect

The trouble with antidepressants: why the evidence overplays benefits and underplays risks—an essay by John B Warren - The BMJ

Depression Drugs Market Size, share | Growth Forecast till 2020-2025 – The Daily Chronicle - The Daily Chronicle

Janssen disappointed with second NICE no for Spravato - PharmaTimes

Combination Therapy for Treatment-Resistant Schizophrenia? - Psychiatric Times

Re: The trouble with antidepressants: why the evidence overplays benefits and underplays risks—an essay by John B Warren - The BMJ

Pages

Main menu

You are here

User login

Articles from Antidepressants

Primary tabs

Pages